What Is the Evidence for the Use of Botulinum Toxin in Idiopathic Detrusor Overactivity?

被引：0
|
作者：
Mangera A. [1 ]
Chapple C.R. [2 ]
机构：
[1] Department of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield
[2] Royal Hallamshire Hospital, Sheffield, S10 2JF, H26, H-Floor, Glossop Road
来源：
Current Bladder Dysfunction Reports | 2011年 / 6卷 / 2期
关键词：
Botulinum toxin; Idiopathic detrusor overactivity; Overactive bladder;
D O I：
10.1007/s11884-011-0088-5
中图分类号：
学科分类号：
摘要：
There is growing evidence to support the use of botulinum toxin (BTX) in idiopathic detrusor overactivity. However, BTX remains off label for this purpose. In this commentary, we review the current status of the literature discussing the evidence for efficacy and safety of BTX. In addition, we present the data regarding the preparation, dose, and administration of BTX. As an emerging treatment, high-level evidence exists for the use of BTX in patients with idiopathic detrusor overactivity; however, details about the optimum number of injection sites and injection volume remain to be answered. In addition, long-term data regarding the effect of repeated injections requires further study. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：70 / 73
页数：3
相关论文
共 50 条
  • [21] Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results
    Patel, Arland K.
    Patterson, Jacob M.
    Chapple, Christopher R.
    EUROPEAN UROLOGY, 2006, 50 (04) : 684 - 710
  • [22] Botulinum Toxin Therapy for Neurogenic Detrusor Overactivity
    Smaldone, Marc C.
    Ristau, Benjamin T.
    Leng, Wendy W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2010, 37 (04) : 567 - +
  • [23] A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin
    Popat, R
    Apostolidis, A
    Kalsi, V
    Gonzales, G
    Fowler, CJ
    Dasgupta, P
    JOURNAL OF UROLOGY, 2005, 174 (03): : 984 - 989
  • [24] Efficacy and complications of intradetrusor injection with botulinum toxin a in patients with refractory idiopathic detrusor overactivity
    Sahai, Arun
    Dowson, Christopher
    Khan, Mohammad Shamim
    Dasgupta, Prokar
    BJU INTERNATIONAL, 2008, 101 (04) : 515 - 516
  • [25] Second-line therapy of idiopathic detrusor overactivity - Sacral neuromodulation and botulinum toxin A
    Amend, B.
    Castro-Diaz, D.
    Chartier-Kastler, E.
    De Ridder, D.
    Everaert, K.
    Spinelli, M.
    van Kereebroeck, P.
    Sievert, K. -D.
    UROLOGE, 2010, 49 (02): : 245 - 252
  • [26] Parameters predicting the response to intradetrusor botulinum a toxin injections in patients with idiopathic detrusor overactivity
    Jeffery, S. T.
    Parappallil, S.
    Wang, K.
    Lee, F.
    Morley, R.
    Fynes, M.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2007, 18 : S64 - S64
  • [27] Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity
    Jeffery, Stephen
    Fynes, Michelle
    Lee, Frank
    Wang, Kate
    Williams, Lin
    Morley, Roland
    BJU INTERNATIONAL, 2007, 100 (06) : 1302 - 1306
  • [28] Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children
    Blackburn, S. C.
    Jones, C.
    Bedoya, S.
    Steinbrecher, H. A.
    Malone, P. S.
    Griffin, S. J.
    JOURNAL OF PEDIATRIC UROLOGY, 2013, 9 (06) : 750 - 753
  • [29] Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin
    Truzzi, Jose Carlos
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) : 128 - 134
  • [30] BOTULINUM TOXIN, TREATMENT OPTION FOR NEUROGENIC DETRUSOR OVERACTIVITY
    Persu, Cristian
    Castro-Diaz, David Manuel
    Jinga, Viorel
    Chirca, Narcis
    Ciofu, Irina
    FARMACIA, 2022, 70 (02) : 198 - 203
12345